DelMar Pharmaceuticals to Present at the Biotech Showcase 2016 on January 12, 2016

DelMar Pharmaceuticals (OTCQX:DMPI) a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that it will present at the 8th Annual Biotech Showcase™ conference on Tuesday, January 12, 2016 at 11:00 a.m. PT in San Francisco, CA.

DelMar Pharmaceuticals (OTCQX:DMPI) a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that it will present at the 8th Annual Biotech Showcase conference on Tuesday, January 12, 2016 at 11:00 a.m. PT in San Francisco, CA.
As quoted in the press release:

Jeffrey Bacha, DelMar’s president and CEO, will provide an update on the Company’s ongoing clinical trial of VAL-083 (dianhydrogalactitol) in patients with recurrent glioblastoma multiforme (GBM) as well as the Company’s goal to “up-list” its shares to a National US Exchange.
During his presentation, Mr. Bacha will review safety and efficacy data from the Phase II refractory GBM study that was recently presented at the Society for Neuro-Oncology Annual Meeting and will provide an update on DelMar’s plans to advance to registration-directed Phase II/III clinical trials in refractory GBM during 2016.
VAL-083 has also demonstrated promising potential to address modern unmet medical needs in the treatment of a range of cancers, including non-small cell lung cancer (NSCLC), ovarian cancers, malignant pediatric brain tumors, and other solid tumor types, especially where other therapies have failed or are predicted to give sub-optimal outcomes.
A live audio webcast of the presentation will be available by accessing DelMar’s IR Calendar in the Investors section of the Company’s website. The webcast replay will be available approximately two hours after the presentation and will be accessible for one month.
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present and meet with investors and potential strategics in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.
Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives. The meeting is being held January 11-13, 2016 in San Francisco, CA at the Parc 55, San Francisco, California.